France defender Mamadou Sakho is suing the world anti-doping agency a whopping sum of £13 million (which is ₦6 billion in Nigeria currency) for damaging his career during his time at Liverpool over drug-test blunder.
The Crystal Palace star was suspended from all football activities in April 2016 after testing positive for a fat-burning substance. The provisional 30-day suspension meant the Eagles star missed out on Liverpool’s 3-1 defeat to Sevilla in the Europa League final 2016 and he claims the ban also cost him a place in France’s Euro 2016 squad which they finished second.
Sakho was finally cleared in disciplinary proceedings before European football governing body (Uefa) after they found the substance (higenamine) was not actually on the banned list. The Eagles defender is now suing for £13 million (₦6 billion ), claiming that his earnings as a professional footballer and the worth of his personal brand have been reduced by his move away from Liverpool.
The World Anti-Doping Agency (Wada) denies claims that it is responsible for his transfer away from Anfield, saying it was caused by “disciplinary issues” and a “personality clash” with Liverpool manager Jurgen Klopp.
At the High Court on Tuesday, Stuart Ritchie QC, representing the Frenchman, said the footballer dropped out of contention for the France national team, had to pay for lawyers and reports to fight the case and left Liverpool in January 2017 for Crystal Palace.
“Although this is a distinguished club, it does not have the worldwide reputation of Liverpool with the value this brings to a player,” he said.
According to reports on Evening Standard, the court heard Mr Sakho had tested positive for the substance — which was present in a dietary supplement he had taken — in a urine test in March 2016. The laboratory wrote to Wada and was told that the substance was on its banned list under “B2-agonists”. But the list did not specifically name higenamine and Uefa found it was “not proven” that it was on the list, clearing Mr Sakho in July 2016.
The Uefa tribunal said there were “significant doubts” whether higenamine is a “B2-agonist” and said there had been a “lack of communication” from Wada about its status. Judge Victoria McCloud has ordered that a trial on liability to determine if Wada was negligent take place before the level of any compensation is decided.

                                            Most accurate football prediction website...